Revlimid (lenalidomide) [product information]. EMA.

Regulatory approval published by the European Medicines Agency.

Citation

Bristol-Myers Squibb Pharma EEIG. Revlimid (lenalidomide) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf. Revised January 2024. Accessed March 28, 2024.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Revlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	5q deletion	Myeloproliferative Neoplasm	Lenalidomide